JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
$254,94
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 3, 2026
52W-Spanne
$118–$265
93% of range
Analystenbewertung
BUY
26 analysts
Kursziel
$281
+10% upside
P/E (TTM)
-29.1
ROE
—
Nettogewinnmarge
—
Über Jazz Pharmaceuticals plc - Ordinary Shares Unternehmensübersicht von Wikipedia
Jazz Pharmaceuticals ist ein irisches biotechnologisches Pharmaunternehmen, das 2003 gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen JAZZ gelistet ist. Seinen Hauptsitz hat Jazz Pharmaceuticals in Dublin, Irland. Das Unternehmen ist spezialisiert auf die Behandlung von Schlafstörungen und Epilepsie und erforscht und liefert in der Onkologie Medikamente für schwer zu behandelnde hämatologische Malignome und solide Tumore.
Mehr lesen
Jazz Pharmaceuticals ist ein irisches biotechnologisches Pharmaunternehmen, das 2003 gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen JAZZ gelistet ist. Seinen Hauptsitz hat Jazz Pharmaceuticals in Dublin, Irland. Das Unternehmen ist spezialisiert auf die Behandlung von Schlafstörungen und Epilepsie und erforscht und liefert in der Onkologie Medikamente für schwer zu behandelnde hämatologische Malignome und solide Tumore.
Medikamente
Jazz Pharmaceuticals hat u. a. folgende Medikamente im Markt:
Epidiolex (USA) / Epidyolex (EU) mit dem Wirkstoff Cannabidiol wird als Zusatztherapie von Krampfanfällen im Zusammenhang mit dem Lennox-Gastaut-Syndrom (LGS) oder dem Dravet-Syndrom (DS) in Verbindung mit Clobazam bei Patienten ab 2 Jahren angewendet.
Sativex (D, AT, CH) mit dem Wirkstoff Cannabis-Dickextrakt (mit eingestellten Gehalten an Tetrahydrocannabinol und Cannabidiol), wird angewendet zur Symptomverbesserung bei erwachsenen Patienten mit mittelschwerer bis schwerer Spastik aufgrund von Multipler Sklerose (MS), die nicht angemessen auf eine andere antispastische Arzneimitteltherapie angesprochen haben und die eine klinisch erhebliche Verbesserung von mit der Spastik verbundenen Symptomen während eines Anfangstherapieversuchs aufzeigen.
Xyrem (USA) mit dem Wirkstoff Natriumoxybat, zugelassen zur Behandlung von Narkolepsie mit Kataplexie bei Patienten ab einem Alter von 7 Jahren.
Xywave mit den Wirkstoffen Calcium-, Magnesium-, Kalium- und Natriumoxybat, zugelassen in den USA und Kanada zur Behandlung einer Kataplexie oder exzessiven Tagesschläfrigkeit (EDS) bei Patienten ab 7 Jahren mit Narkolepsie
Rylaze (USA) / Enrylaze (EU) mit dem Wirkstoff Crisantaspase zur Behandlung der akuten lymphatischen Leukämie (ALL) und des lymphoblastischen Lymphoms (LBL).
Geschichte
Jazz Pharmaceuticals wurde 2003 gegründet und wuchs primär durch den Zukauf von Produkten (z. B. Xyrem) und Zusammenschlüssen (Mergers) mit anderen Pharmaunternehmen (z. B. Azur Pharma, EUSA Pharma, Gentium, Celator etc.).
Im Mai 2021 gab Jazz Pharmaceuticals den Abschluss der Übernahme von GW Pharmaceuticals (Nasdaq: GWPH) bekannt, einem führenden Unternehmen in der Wissenschaft, Entwicklung und Vermarktung von verschreibungspflichtigen Medikamenten auf Cannabinoidbasis.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
JAZZ Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$254.94
Marktkapitalisierung
—
P/E (TTM)
-29.1
EPS (TTM)
$-5.84
Umsatz (TTM)
$4.27B
Dividendenrendite
—
ROE
—
Verschuldungsgrad
—
52W-Spanne
$118 – $265
JAZZ Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$4.27B
2016-12-31
→
2025-12-31
EPS
$-5.84
2016-12-31
→
2025-12-31
Freier Cashflow
—
Margen
—
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
JAZZ
Peer-Median
P/E (TTM)
-29.1
530.6
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
JAZZ
Peer-Median
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
JAZZ
Peer-Median
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
JAZZ
Peer-Median
Revenue YoY (Umsatz YoY)
4.9%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
5.3%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
12.5%
—
EPS YoY (EPS VjV)
41.8%
—
Net Income YoY (Nettogewinn YoY)
35.0%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
JAZZ
Peer-Median
JAZZ Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
26 Analysten
- Starker Kauf 7 26,9%
- Kauf 17 65,4%
- Halten 2 7,7%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
20 Analysten · 2026-08-15
Median
$285.00
Jetzt
$254.94
Tief
$196.00
Hoch
$315.00
Median-Ziel
$285.00
+11,8%
Mittelwert-Ziel
$281.10
+10,3%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.06%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $5.71 | $6.30 | -0.59% |
| 31. März 2026 | $6.34 | $4.66 | 1.7% |
| 31. Dezember 2025 | $6.64 | $6.65 | -0.01% |
| 30. September 2025 | $8.13 | $6.04 | 2.1% |
| 30. Juni 2025 | $-8.25 | $-7.76 | -0.49% |
| 31. März 2025 | $1.68 | $4.75 | -3.1% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| JAZZ | — | -29.1 | 4.9% | — | — | — |
| GHRS | — | — | — | — | — | — |
| PRGO | $1.92B | -1.4 | -2.8% | -33.5% | -38.5% | 35.1% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Bilanz 26
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Cashflow 12
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Wachstumsraten 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | -121,888,000 | 60,696,000 | 61,200,000 | 61,000,000 | -124,995,000 | 61,414,000 | 62,882,000 | 62,537,000 | -127,308,000 | 63,114,000 | 63,991,000 | 63,494,000 | -124,547,000 | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | -122,798,000 | 61,606,000 | 61,200,000 | 61,000,000 | -129,329,000 | 63,174,000 | 69,625,000 | 62,537,000 | -146,538,000 | 71,293,000 | 73,540,000 | 73,771,000 | -126,584,000 | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Bilanz 24
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Liquidität & Solvenz 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Bewertung (TTM) 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.45B | $4.14B | · | $4.12B | $4.02B | $3.88B | · | $3.95B | $3.86B | $3.72B | · | $3.76B | $3.72B | $3.58B | · | $3.53B | |
| Net Income TTM | $19M | $-266M | · | $-345M | $-427M | $276M | · | $516M | $405M | $306M | · | $301M | $189M | $86M | · | $-36M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | -535.5 | -39.8 | · | -22.9 | -14.4 | 29.8 | · | 14.2 | 18.0 | 26.9 | · | 29.5 | 44.3 | 111.7 | · | -225.9 | |
| P/S | 3.5 | 2.9 | · | 1.9 | 1.6 | 2.0 | · | 1.7 | 1.7 | 2.0 | · | 2.2 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| P / FCF | · | 30.5 | · | · | · | 18.4 | · | · | · | 29.2 | · | · | · | · | · | · | |
| EV / EBITDA | 73.9 | 45.6 | · | 209.4 | -15.5 | -199.6 | · | 40.8 | 54.9 | 179.1 | · | 72.7 | · | · | · | · | |
| EV / FCF | · | 39.5 | · | · | · | 26.8 | · | · | · | 45.5 | · | · | · | · | · | · | |
| EV / Revenue | 4.1 | 3.7 | · | 2.9 | 2.6 | 2.9 | · | 2.7 | 2.8 | 3.2 | · | 3.3 | · | · | · | · | |
| Earnings Yield | -0.19% | -2.5% | · | -4.4% | -6.9% | 3.4% | · | 7.0% | 5.5% | 3.7% | · | 3.4% | 2.3% | 0.90% | · | -0.44% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Nettoergebnis | $-356M | $560M | $415M | $-224M | $-330M |
| Verwässerte EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 692 Einreicher · $9.8B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 145 (+42 vs. Vorquartal) | 56 (-21 vs. Vorquartal) | 220 (+19 vs. Vorquartal) | 190 (+12 vs. Vorquartal) | -1.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $846.470.147 | 3.512.762 | 8,60% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731.636.247 | 3.036.213 | 7,43% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $657.763.761 | 2.729.650 | 6,68% | Aktien |
| Capital World Investors | $650.043.082 | 2.697.610 | 6,60% | Aktien |
| STATE STREET CORP | $481.895.662 | 1.999.816 | 4,89% | Aktien |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394.839.917 | 1.638.544 | 4,01% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $390.196.222 | 1.619.274 | 3,96% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $297.928.728 | 1.236.065 | 3,03% | Aktien |
| AMERIPRISE FINANCIAL INC | $260.580.996 | 1.081.421 | 2,65% | Aktien |
| CITADEL ADVISORS LLC | $242.578.716 | 1.006.676 | 2,46% | Aktien |
| Swedbank AB | $233.208.837 | 967.792 | 2,37% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $184.072.164 | 763.880 | 1,87% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $165.478.678 | 686.719 | 1,68% | Aktien |
| NORGES BANK | $158.279.458 | 656.843 | 1,61% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $135.442.731 | 562.073 | 1,38% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129.891.746 | 539.037 | 1,32% | Aktien |
| Allianz Asset Management GmbH | $122.925.785 | 510.129 | 1,25% | Aktien |
| GMT Capital Corp | $109.279.895 | 453.500 | 1,11% | Aktien |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105.278.106 | 436.893 | 1,07% | Aktien |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103.893.734 | 431.148 | 1,06% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $96.439.086 | 400.212 | 0,98% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $95.008.929 | 394.277 | 0,96% | Aktien |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $89.279.867 | 370.502 | 0,91% | Aktien |
| Sofinnova Investments, Inc. | $88.036.221 | 365.341 | 0,89% | Aktien |
| Polaris Capital Management, LLC | $79.270.937 | 328.966 | 0,81% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $77.695.234 | 322.427 | 0,79% | Aktien |
| Bank of New York Mellon Corp | $76.961.481 | 319.382 | 0,78% | Aktien |
| GOLDENTREE ASSET MANAGEMENT LP | $70.838.675 | 294.435 | 0,72% | Aktien |
| Qube Research & Technologies Ltd | $70.056.003 | 290.725 | 0,71% | Aktien |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66.815.854 | 277.279 | 0,68% | Aktien |
| Quantinno Capital Management LP | $65.906.960 | 273.506 | 0,67% | Aktien |
| Boston Trust Walden Corp | $64.110.068 | 266.050 | 0,65% | Aktien |
| BANK OF AMERICA CORP /DE/ | $60.589.497 | 251.440 | 0,62% | Aktien |
| Tri Locum Partners LP | $53.427.868 | 221.720 | 0,54% | Aktien |
| Iron Triangle Partners LP | $49.668.900 | 292.170 | 0,50% | Aktien |
| ARGENT CAPITAL MANAGEMENT LLC | $48.211.350 | 200.072 | 0,49% | Aktien |
| GOLDMAN SACHS GROUP INC | $45.527.185 | 188.933 | 0,46% | Aktien |
| PERCEPTIVE ADVISORS LLC | $40.964.900 | 170.000 | 0,42% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $39.434.259 | 163.648 | 0,40% | Aktien |
| RHUMBLINE ADVISERS | $39.282.382 | 163.018 | 0,40% | Aktien |
| Holocene Advisors, LP | $38.794.001 | 160.991 | 0,39% | Aktien |
| Saturn V Capital Management LP | $38.781.230 | 160.938 | 0,39% | Aktien |
| PFM Health Sciences, LP | $38.740.265 | 160.768 | 0,39% | Aktien |
| Retirement Systems of Alabama | $38.473.993 | 159.663 | 0,39% | Aktien |
| Woodline Partners LP | $36.165.501 | 150.083 | 0,37% | Aktien |
| LOOMIS SAYLES & CO L P | $35.355.338 | 146.721 | 0,36% | Aktien |
| Pictet Asset Management Holding SA | $35.115.175 | 147.599 | 0,36% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $34.163.762 | 141.776 | 0,35% | Aktien |
| STIFEL FINANCIAL CORP | $33.583.066 | 139.365 | 0,34% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $33.026.625 | 137.057 | 0,34% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $32.383.478 | 134.388 | 0,33% | Aktien |
| California Public Employees Retirement System | $30.759.098 | 127.647 | 0,31% | Aktien |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $30.249.134 | 160.006 | 0,31% | Aktien |
| Robeco Institutional Asset Management B.V. | $28.340.967 | 117.612 | 0,29% | Aktien |
| Gotham Asset Management, LLC | $26.992.014 | 112.014 | 0,27% | Aktien |
| Aristotle Capital Management, LLC | $26.915.626 | 111.697 | 0,27% | Aktien |
| Swiss National Bank | $26.771.767 | 111.100 | 0,27% | Aktien |
| STOREBRAND ASSET MANAGEMENT AS | $26.309.828 | 109.183 | 0,27% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $25.928.372 | 107.600 | 0,26% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $25.286.187 | 104.935 | 0,26% | Aktien |
| BlackRock, Inc. | $23.889.284 | 99.138 | 0,24% | Aktien |
| Perpetual Ltd | $23.733.376 | 98.491 | 0,24% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $23.658.917 | 98.182 | 0,24% | Aktien |
| MORGAN STANLEY | $23.519.795 | 97.604 | 0,24% | Aktien |
| Man Group plc | $23.299.389 | 96.690 | 0,24% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22.868.053 | 94.900 | 0,23% | Verkaufsoption |
| ENVESTNET ASSET MANAGEMENT INC | $22.061.835 | 91.554 | 0,22% | Aktien |
| Rhenman & Partners Asset Management AB | $21.070.417 | 87.440 | 0,21% | Aktien |
| Aberdeen Group plc | $20.146.538 | 83.606 | 0,20% | Aktien |
| Amundi | $19.114.464 | 79.323 | 0,19% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.916.145 | 78.500 | 0,19% | Kaufoption |
| Schonfeld Strategic Advisors LLC | $18.620.232 | 77.272 | 0,19% | Aktien |
| FIRST TRUST ADVISORS LP | $18.149.860 | 75.320 | 0,18% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $17.765.513 | 73.725 | 0,18% | Aktien |
| LAZARD ASSET MANAGEMENT LLC | $16.768.620 | 69.588 | 0,17% | Aktien |
| Longaeva Partners L.P. | $16.576.808 | 68.792 | 0,17% | Aktien |
| Simplify Asset Management Inc. | $16.520.903 | 68.560 | 0,17% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $16.497.448 | 87.265 | 0,17% | Aktien |
| Distillate Capital Partners LLC | $16.167.159 | 67.092 | 0,16% | Aktien |
| SEB Asset Management AB | $15.890.255 | 65.943 | 0,16% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $15.380.484 | 64.700 | 0,16% | Aktien |
| SEI INVESTMENTS CO | $14.931.224 | 61.963 | 0,15% | Aktien |
| Illinois Municipal Retirement Fund | $14.911.947 | 61.883 | 0,15% | Aktien |
| Tweedy, Browne Co LLC | $14.494.105 | 60.149 | 0,15% | Aktien |
| MARTINGALE ASSET MANAGEMENT L P | $14.335.788 | 59.492 | 0,15% | Aktien |
| DeepCurrents Investment Group LLC | $14.132.168 | 58.647 | 0,14% | Aktien |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $13.348.774 | 55.396 | 0,14% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $12.952.138 | 53.750 | 0,13% | Aktien |
| ExodusPoint Capital Management, LP | $12.819.845 | 53.201 | 0,13% | Aktien |
| Squarepoint Ops LLC | $12.807.074 | 53.148 | 0,13% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.034.356 | 63.657 | 0,12% | Aktien |
| ALGERT GLOBAL LLC | $11.749.697 | 48.760 | 0,12% | Aktien |
| CASTLEARK MANAGEMENT LLC | $11.306.312 | 46.920 | 0,11% | Aktien |
| CITADEL ADVISORS LLC | $11.253.299 | 46.700 | 0,11% | Kaufoption |
| RENAISSANCE GROUP LLC | $11.221.601 | 46.568 | 0,11% | Aktien |
| Nuveen, LLC | $11.184.623 | 46.415 | 0,11% | Aktien |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $10.859.795 | 45.067 | 0,11% | Aktien |
| Foundry Partners, LLC | $10.730.160 | 86.429 | 0,11% | Aktien |
| Legal & General Group Plc | $10.402.916 | 43.171 | 0,11% | Aktien |
| DEAN INVESTMENT ASSOCIATES, LLC | $10.273.274 | 42.633 | 0,10% | Aktien |
Unternehmensinsider 50 Insider · 4 Führungskräfte · 4 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 30. Juni 2026 F | 147.361 | 0 | 0 | $0 |
| Philip L Johnson | EVP & Chief Financial Officer | 30. Juni 2026 F | 56.431 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 30. Juni 2026 F | 48.871 | 0 | 2 | $-560.664 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 30. Juni 2026 F | 85.107 | 0 | 0 | $0 |
| Bryan C Cressey | Direktor | 9. März 2012 S | 27.631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Direktor | 10. März 2011 A | — | 0 | 0 | $0 |
| Alexander E Albert | Direktor | 15. August 2008 A | — | 0 | 0 | $0 |
| Patel Jaimin | Direktor | 15. August 2007 A | — | 0 | 0 | $0 |
| Patrick Kennedy | — | 5. August 2026 A | 8.307 | 0 | 0 | $0 |
| Samantha Pearce | — | 5. August 2026 F | 47.131 | 0 | 1 | $-1.625.977 |
| Mark Douglas Smith | — | 5. August 2026 A | 11.285 | 0 | 1 | $-266.746 |
| Jennifer E. Cook | — | 5. August 2026 A | 12.442 | 0 | 0 | $0 |
| Laura Hamill | — | 5. August 2026 A | 8.538 | 0 | 0 | $0 |
| Heather Ann Mcsharry | — | 5. August 2026 A | 20.054 | 0 | 0 | $0 |
| Seamus Mulligan | — | 5. August 2026 A | 1.184.633 | 0 | 0 | $0 |
| Rick E Winningham | — | 5. August 2026 A | 11.172 | 0 | 2 | $-1.656.873 |
| Patrick G. Enright | — | 5. August 2026 A | 22.984 | 0 | 0 | $0 |
| Bruce C Cozadd | — | 5. August 2026 A | 362.287 | 0 | 20 | $-25.646.326 |
| Ted W Love | — | 5. August 2026 A | 3.132 | 0 | 0 | $0 |
| Norbert G Riedel | — | 5. August 2026 A | 8.629 | 0 | 1 | $-655.680 |
| Kenneth W O'Keefe | — | 2. Dezember 2025 F | 25.811 | 0 | 0 | $0 |
| Daniel N Swisher JR | — | 3. Januar 2019 F | 16.512 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | — | 14. Dezember 2018 M | 41.184 | 0 | 0 | $0 |
| Matthew P. Young | — | 23. November 2018 S | 32.068 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | — | 13. November 2018 S | 24.972 | 0 | 0 | $0 |
| Paul Treacy | — | 10. August 2018 S | 17.458 | 0 | 0 | $0 |
| Elmar Schnee | — | 9. August 2018 A | 6.094 | 0 | 0 | $0 |
| Peter Gray | — | 9. August 2018 A | 8.182 | 0 | 0 | $0 |
| Catherine A. Sohn | — | 9. August 2018 A | 7.654 | 0 | 0 | $0 |
| Paul L Berns | — | 9. August 2018 A | 6.772 | 0 | 0 | $0 |
| Karen J Wilson | — | 11. Mai 2018 S | 15.757 | 0 | 0 | $0 |
| Karen L. Smith | — | 5. März 2018 F | 28.474 | 0 | 0 | $0 |
| Iain Mcgill | — | 5. März 2018 F | 22.048 | 0 | 0 | $0 |
| Russell J. Cox | — | 6. März 2017 F | 52.795 | 0 | 0 | $0 |
| Jeffrey K Tobias | — | 5. März 2015 F | 38.484 | 0 | 0 | $0 |
| Fintan Keegan | — | 8. Juli 2014 M | 31.750 | 0 | 0 | $0 |
| Kathryn E Falberg | — | 5. März 2014 F | 133.387 | 0 | 0 | $0 |
| James C Momtazee | — | 13. August 2013 S | 17.315 | 0 | 0 | $0 |
| Carol A Gamble | — | 9. März 2012 S | 32.213 | 0 | 0 | $0 |
| Alan Sebulsky | — | 9. März 2012 S | 54.355 | 0 | 0 | $0 |
| Samuel D Colella | — | 11. Januar 2012 M | 38.347 | 0 | 0 | $0 |
| Michael W Michelson | — | 11. Januar 2012 M | 13.885 | 0 | 0 | $0 |
| Mark G. Eller | — | 13. August 2011 M | 4.151 | 0 | 0 | $0 |
| Michael A. Desjardin | — | 13. August 2011 M | 14.574 | 0 | 0 | $0 |
| Janne Lt Wissel | — | 31. Mai 2011 J | 48.544 | 0 | 0 | $0 |
| Joan Colligan | — | 30. November 2010 J | 14.424 | 0 | 0 | $0 |
| Robert M Myers | — | 30. November 2010 J | 156.898 | 0 | 0 | $0 |
| James B Tananbaum | — | 25. August 2010 A | 21.366 | 0 | 0 | $0 |
| Samuel R Saks | — | 21. Januar 2009 A | 358.868 | 0 | 0 | $0 |
| Matthew K Fust | — | 28. November 2008 J | 58.948 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 6 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 Einreichungen | 20. Juni 2014 | — | Erste Einreichung | — | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 Einreichungen | 12. März 2013 | — | Erste Einreichung | — | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 Einreichungen | 14. März 2012 | — | Erste Einreichung | Kapitalstruktur | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 Einreichungen | 30. September 2011 | — | Erste Einreichung | — | SEC |
| Azur Pharma Limited | 28. September 2011 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 28. April 2005 | — | Erste Einreichung | M&A / Verkauf | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 72 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,47% | 931 NS | 30. April 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,50% | 14.803 NS | 30. April 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,49% | 12.809 NS | 31. Mai 2026 | N-PORT |
| AVLV · AMERICAN CENTURY ETF TRUST | 0,28% | 154.718 NS | 31. Mai 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,25% | 169.973 NS | 30. April 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,24% | 1.006 NS | 30. April 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,23% | 14.796 NS | 30. April 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,20% | 3.508 NS | 31. Mai 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,17% | 113.983 NS | 30. April 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,16% | 59.597 NS | 30. April 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,15% | 1.679 NS | 31. Mai 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,14% | 59 NS | 31. Mai 2026 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,13% | 2.492 NS | 31. Mai 2026 | N-PORT |
| AVLC · AMERICAN CENTURY ETF TRUST | 0,08% | 4.239 NS | 31. Mai 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,08% | 42.911 NS | 31. Mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,07% | 2.294 NS | 31. Mai 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,07% | 147.813 NS | 30. April 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,06% | 45.962 NS | 30. April 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,05% | 7.081 NS | 30. April 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 13.414 NS | 30. April 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,02% | 434 NS | 30. April 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,02% | 17.653 NS | 30. April 2026 | N-PORT |
| MSLC · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 2.233 NS | 31. Mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VBR · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | — | — | 30. Juli 2026 | Täglich |
| VFVA · VANGUARD WELLINGTON FUND | — | — | 30. Juli 2026 | Täglich |
| VFMF · VANGUARD WELLINGTON FUND | — | — | 30. Juli 2026 | Täglich |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15. Juli 2026 | Täglich |
| IVOO · VANGUARD ADMIRAL FUNDS | — | — | 15. Juli 2026 | Täglich |
| IVOG · VANGUARD ADMIRAL FUNDS | — | — | 15. Juli 2026 | Täglich |
| VONE · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| VONV · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| IJH · iShares Trust | — | — | 18. August 2026 | Täglich |
| IJK · iShares Trust | — | — | 7. August 2026 | Täglich |
| ITOT · iShares Trust | — | — | 22. Juli 2026 | Täglich |
| IWS · iShares Trust | — | — | 18. August 2026 | Täglich |
| IWR · iShares Trust | — | — | 7. August 2026 | Täglich |
| IUSG · iShares Trust | — | — | 6. August 2026 | Täglich |
| IWV · iShares Trust | — | — | 18. August 2026 | Täglich |
| IWD · iShares Trust | — | — | 14. August 2026 | Täglich |
| IWB · iShares Trust | — | — | 18. August 2026 | Täglich |
| IHE · iShares Trust | — | — | 18. August 2026 | Täglich |
| SMMD · iShares Trust | — | — | 18. August 2026 | Täglich |
| XJH · iShares Trust | — | — | 6. August 2026 | Täglich |
| PJP · Invesco Exchange-Traded Fund Trust | — | — | 6. August 2026 | Täglich |
| PRF · Invesco Exchange-Traded Fund Trust | — | — | 6. August 2026 | Täglich |